Jazz Pharmaceuticals plc (JAZZ) Tuesday reported first-quarter net income of $43.4 million or $0.71 per share, up from $27.7 million or $0.48 per share last year.
Adjusted net income for the first quarter was $84.4 million or $1.37 per share, up from $51.7 million or $0.89 per share last year.
Total revenues for the quarter grew to $196.2 million from $102.5 million last year.
Analysts polled by Thomson Reuters estimated earnings of $1.35 per share on revenues of $189.82 million for the quarter. Analysts' estimates typically exclude special items.
The company lifted its earnings guidance for the full year 2013. The company now expects earnings of $3.32 to $3.69 per share, adjusted earnings of $6.10 to $6.30 per share and revenues of $830 million to $860 million.
Analysts currently estimate earnings of $5.87 per share on revenues of $825.48 million for the quarter.
Previously, the company expected earnings of $3.17 to $3.47 per share, adjusted earnings of $5.70 to $5.90 per share, and revenues of $805 million to $835 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.